her2 positive breast cancer icd 10

Release time ：Dec-13,2024

HER2-positive breast cancer, classified as C50.912 in the ICD-10 coding system, is a particularly aggressive form of breast cancer characterized by an overabundance of the human epidermal growth factor receptor 2 (HER2) protein on the surface of cancer cells. This subtype tends to be more invasive and has a higher likelihood of spreading compared to other breast cancer types.

Treatment for HER2-positive breast cancer typically involves a multimodal approach. Surgery is a primary treatment method, which may include breast-conserving surgery or total mastectomy. Adjuvant chemotherapy is also a crucial component to reduce the risk of relapse and prolong survival. Additionally, patients with HER2-positive tumors may benefit from targeted therapies such as trastuzumab (Herceptin), which binds to the HER2 receptor to inhibit cancer cell growth signals, thereby controlling tumor progression. The necessity of radiotherapy is determined on a case-by-case basis, considering the patient's specific circumstances and postoperative pathology results.

Patients should maintain a positive outlook and actively engage with their healthcare providers' treatment plans, including regular follow-ups. A balanced diet and regular physical activity can also contribute to enhancing overall health and immune function. Medication adherence is critical; patients must strictly follow their doctor's instructions regarding dosage and medication regimen, avoiding any self-directed changes that could compromise treatment efficacy. Should any concerns or side effects arise, prompt medical consultation is advised.